Selective group III metabotropic glutamate receptor antagonist in some electrophysiological systems. Group II/group III agonist in certain neurochemical systems.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|phosphate buffered saline||19.71||100|
Preparing Stock Solutions
The following data is based on the product molecular weight 197.13. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.07 mL||25.36 mL||50.73 mL|
|5 mM||1.01 mL||5.07 mL||10.15 mL|
|10 mM||0.51 mL||2.54 mL||5.07 mL|
|50 mM||0.1 mL||0.51 mL||1.01 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Jane et al (1994) Actions of two new sub-type selective metabotropic glutamate receptor antagonists in the neonatal rat spinal cord. Br.J.Pharmacol. 112 809 PMID: 7921606
Kemp et al (1996) Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices. Eur.J.Pharmacol. 309 79 PMID: 8864697
Salt and Eaton (1995) Distinct presynaptic metabotropic receptors for L-AP4 and CCGl on GABAergic terminals: pharmacological evidence using novel α-methyl derivative mGluR antagonists, MAP4 and MCCG, in the rat thalamus in vivo. Neuroscience 65 5 PMID: 7753406
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
If you know of a relevant reference for MAP4, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Potent group II mGlur agonists specific III antagonists Selective potent Group Receptors mGlu2 mGlu3 mGluR2 mGluR3 Glutamate Metabotropic mGlu4 mGluR4 mGlu6 mGluR6 mGlu7 mGluR7 mGlu8 mGlkuR8 Glutamate (Metabotropic) Group II Receptors
1 Citation for MAP4
Citations are publications that use Tocris products. Selected citations for MAP4 include:
Piet et al (2004) Physiological contribution of the astrocytic environment of neurons to intersynaptic crosstalk. J Neurosci 101 2151 PMID: 14766975
Do you know of a great paper that uses MAP4 from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.